The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies

Published

Journal Article (Review)

High-dose chemotherapy supported by autologous stem-cell transplantation has been widely evaluated as a strategy for high-risk patients with breast cancer. Peripheral blood progenitor cells (PBPC) have replaced over the years as the source of autologous hematopoietic graft. Hematopoietic growth factors have been studied extensively in this setting to optimize stem-cell mobilization techniques and allow a more rapid engraftment after transplantation. This article therefore provides the rationale and clinical uses of the different growth factors, such as granulocyte colony-stimulating factor (GM-CSF), Granulocyte-macrophage colony-stimulating, stem-cell factor, thrombopoietin, and rhIL-11, to support breast cancer patients undergoing dose intensive therapies. New strategies like ex-vivo expansion are also discussed. Copyright (C) 2000 by W.B. Saunders Company.

Duke Authors

Cited Authors

  • Beaudet, J; Mcniece, IK; Jones, RB; Bearman, SI; Cagnoni, PJ; Nieto, Y; Mcsweeney, P; Shpall, EJ

Published Date

  • January 1, 2000

Published In

Volume / Issue

  • 3 / 3

Start / End Page

  • 144 - 152

International Standard Serial Number (ISSN)

  • 1092-4450

Citation Source

  • Scopus